5.30Open5.66Pre Close13 Volume29 Open Interest20.00Strike Price6.96KTurnover106.39%IV5.82%PremiumDec 20, 2024Expiry Date4.57Intrinsic Value100Multiplier18DDays to Expiry1.43Extrinsic Value100Contract SizeAmericanOptions Type0.8416Delta0.0418Gamma4.77Leverage Ratio-0.0411Theta0.0076Rho4.01Eff Leverage0.0131Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet